Ensysce Biosciences (ENSC) is a micro-cap clinical-stage biotechnology company developing proprietary TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance) prodrug platforms for abuse- and overdose-resistant prescription opioids and CNS therapeutics; it has recently advanced clinical trials, secured significant non-dilutive funding and a major acquisition/financing package, but faces typical biotech risks including high cash burn, dilution history, and limited commercial validation.
Fact: ENSC has experienced extreme long-term volatility and value erosion, including multiple reverse stock splits (e.g., 1-for-15 effective December 2024, 1-for-20 in 2022) and trading in the sub-$1 range for extended periods after going public via SPAC in 2021.
Interpretation: Performance reflects the high-risk nature of early-stage biotech development, frequent equity raises, and sensitivity to clinical/news catalysts rather than operational revenue.
Uncertainty: Short-term movements are heavily driven by announcements; sustained recovery depends on trial success and commercialization milestones whose outcomes remain unproven.
| Period | Approximate Return | Notes |
|---|---|---|
| YTD (as of early Aug 2026 data) | Mixed/volatile (reports range from negative to modestly positive pre-latest news) | Significant daily swings (e.g., +37% on Aug 4, 2026) |
| 1-Year | Approximately -77% to -82% | 52-week range ~$0.23 – $2.75 |
| Longer-term (post-2021 SPAC) | Severe declines (multi-year losses exceeding 90% in some periods) | Impacted by reverse splits and dilution |
Yahoo Finance Historical Data & Chart | Macrotrends 8-Year History
Fact: As a clinical-stage company, ENSC generates minimal product revenue (primarily grants or collaborations); trailing twelve months revenue ~$4.7M with net losses of ~$11.8M and negative profitability margins (profit margin ~-250%).
Fact: Balance sheet shows low cash reserves pre-recent events ($745k as of Mar 31, 2026 vs. $4.3M at Dec 31, 2025); high burn rate typical of R&D-focused biotech.
Interpretation: The company relies on grants (e.g., NIDA), equity financings, and now the announced Cy Biopharma acquisition plus up to $77M private financing to extend runway.
Uncertainty: Post-acquisition and financing cash position and dilution impact are not yet fully reflected in older filings; future revenue depends on successful clinical advancement and partnerships.
| Metric | Value | Period |
|---|---|---|
| Revenue (TTM) | ~$4.7M – $5.1M | FY2025 / TTM |
| Net Income / Loss | -$10.2M to -$11.8M | FY2025 / TTM |
| EPS (Diluted) | ~- $3.11 to -$3.98 | TTM / FY2025 |
| Cash & Equivalents | $745k | Mar 31, 2026 |
| Employees | ~8–9 | Recent |
Company IR Financial Filings & Presentations | Yahoo Finance Financials
Fact: Coverage is extremely limited (typically 1–7 analysts cited across sources, with the most recent specific rating from HC Wainwright & Co. in September 2023: Maintain Buy, price target lowered from $9 to $7).
Fact: Aggregated targets appear in the $16+ range in some platforms, implying substantial upside from then-current levels.
Interpretation: The "Strong Buy" or high-target consensus in limited-coverage sources reflects optimism about the TAAP/MPAR platforms' potential in the opioid abuse-deterrence space, but such targets for micro-cap biotechs are often aspirational and infrequently updated.
Uncertainty: With minimal active analyst following, ratings may not reflect current clinical or financial developments (e.g., 2026 trial enrollment and funding news); targets can quickly become outdated.
| Source | Consensus/Target | Rating | Date |
|---|---|---|---|
| HC Wainwright | $7 (lowered from $9) | Buy | Sep 2023 |
| Various aggregators | ~$16.45–$16.78 (1–7 analysts) | Strong Buy (limited sample) | Recent snapshots |
Yahoo Finance Analyst Insights | Investing.com Consensus
Fact: As a pre-commercial clinical-stage company, ENSC has no approved products and thus no traditional end customers or meaningful product revenue from sales.
Interpretation: Potential future customers would be patients with severe/chronic pain or ADHD via prescriptions, or pharmaceutical partners for licensing/commercialization of the TAAP/MPAR platforms.
Uncertainty: Successful market entry depends on FDA approval, reimbursement, and adoption of abuse-deterrent formulations, which have faced mixed real-world evidence on impact versus cost.
Fact: Direct competition exists in the abuse-deterrent opioid (ADF) space from approved products and other developers; broader peers are small-cap biotechs in pain/CNS or reformulation technologies.
| Company | Focus | Status/Notes |
|---|---|---|
| Collegium Pharmaceutical (COLL) | Xtampza ER (oxycodone ADF) | Approved ADF product |
| Pacira BioSciences (PCRX) | Pain management (non-opioid focus) | Commercial-stage |
| Zevra Therapeutics (ZVRA) | CNS/orphan drugs | Clinical/commercial mix |
| Aquestive Therapeutics (AQST) | Drug delivery technologies | Clinical/commercial |
| Small peers (e.g., ARTL, SILO) | Biotech/pain or CNS | Early-stage, similar market cap |
Historical ADF examples: OxyContin TR, Hysingla ER, Embeda, etc. (various manufacturers).
Fact: Founded in 2003 and headquartered in La Jolla, California; develops prodrug technologies to release active drugs only under specific physiological conditions (TAAP) or provide overdose protection (MPAR when combined).
Fact: Went public in 2021 via merger with SPAC Leisure Acquisition Corp. (LACQ); pipeline includes PF614 (TAAP oxycodone for pain), PF614-MPAR (overdose protection), amphetamine prodrugs (ADHD), and PF9001 (opioid use disorder).
Fact: Received FDA Fast Track and Breakthrough Therapy designations for certain candidates.
Interpretation: The technology aims to address the opioid epidemic by chemistry-based deterrence rather than formulation alone.
Uncertainty: Platform success hinges on clinical data and regulatory outcomes that are still in progress.